Artikelen door Fabian Pruissen

ProPharma Group Announces the Acquisition of Xendo

ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Xendo Holding B.V. (“Xendo”), a Netherlands-based provider of compliance consulting, engineering & technical support, regulatory affairs, and pharmacovigilance services to the (bio)pharmaceutical, medical device and healthcare industries. The acquisition of Xendo also includes Sofus Regulatory Affairs AB, based in Sweden.  “We are […]

Eerste Royalty’s betaald aan het Benefit-sharing Fonds van de Treaty gebaseerd op CGN materiaal

Nunhems Netherlands b.v., gespecialiseerd in groenterassen, heeft $ 119 083 betaald aan het Benefit-sharing Fonds van de International Treaty. Dit komt overeen met 0,77% van de omzet van tien groenterassen, die ontwikkeld zijn op basis van o.a. materiaal verkregen van twee genenbanken, waaronder het Centrum voor Genetische Bronnen, Nederland (CGN). In 2010 heeft Nunhems Netherlands […]

Cleara Biotech Announces Three Collaborations to Develop New Therapeutics Targeting Senescent Cells and Cancer

Cleara Biotech, a Netherlands-based biopharmaceutical company, announced today the creation of three public-private partnerships to discover and develop new therapeutics. Cleara has partnered with Dr. Peter de Keizer from the University Medical Center in Utrecht, Dr. Marco Demaria from the University Medical Center in Groningen, and Dr. Tobias Madl from the Medical University of Graz […]

Eisai and Biogen announce positive topline results

Eisai and Biogen announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer’s Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated […]

Data show Imnovid-based triple therapy PFS benefit in blood cancer

Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone. According to results of the Phase III OPTIMISMM trial, adding Imnovid (pomalidomide) to Velcade (bortezomib) and low-dose dexamethasone significantly extended PFS to 11.2 months compared to […]

EUROSTARS grants project funding for IMMUNOMONITOR consortium led by ENPICOM

A total grant sum of EUR 2 million has been awarded to a multidisciplinary EUROSTARS consortium. The EUROSTARS project is titled “Treatment Response Monitoring for Cancer Immunotherapies Using Immune Repertoire Analysis” and named IMMUNOMONITOR. This European consortium consists of five collaborating partners: ENPICOM (Netherlands), a bioinformatics and software engineering company; Biomax Informatics (Germany), a knowledge […]

,

Trend analysis: Great year for Dutch biotech R&D

Today, the leading global business development database Biotechgate presents its 2018 trend report for the Dutch life sciences market. The annual trend report confirms the top position of the Netherlands in the life sciences industry. For the Dutch biotech research and development efforts, 2017 proved to be remarkably fruitful. The development pipeline contains more products […]